Immunoglobulin subclass levels in patients with non-Hodgkin lymphoma

Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
International Journal of Cancer (Impact Factor: 5.09). 06/2009; 124(11):2616-20. DOI: 10.1002/ijc.24245
Source: PubMed


Allergy/atopy has been suggested to protect against non-Hodgkin lymphoma (NHL) and specific IgE levels are decreased in patients with NHL. We speculated that all immunoglobulin subclass levels might be downregulated in NHL and examined levels of IgM, IgD, IgA, IgE, IgG and IgG(4) in 200 NHL patients and 200 age- and sex-matched controls. Patients with B-cell NHL of many types had consistently lower median immunoglobulin subclass levels than controls. In every subclass except IgD, about 10-15% of B-cell NHL patients had absolute levels below the 2.5 percentile of controls. Subclass levels correlated with each other and many patients had more than one significantly low level. Levels were lowest for IgG(4) and IgE. Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma had especially low total IgE levels. In other B-cell NHL types, total IgE levels were decreased to a similar extent as other immunoglobulin subclasses. In conclusion, low IgE levels are only part of a more generalized loss of immunoglobulins of all subtypes in a wide variety of B-cell NHL types. Low immunoglobulin levels appear to be a consequence of B-cell NHL presence, and we speculate about molecular mechanisms that could reduce all immunoglobulin subclasses in B-cell NHL.

Download full-text


Available from: Michael Christiansen, Jul 21, 2015
23 Reads
  • Source
    • "Five Liberian plasma samples with high concentrations of anti-malaria IgG1 and IgG3 antibodies as determined by a parasite extract ELISA [45] were pooled (HIG). The concentrations of IgG1-4 in HIG and NIG were 8.8 mg/ml, 2.6 mg/ml, 2.2 mg/ml, and 0.4 mg/ml; and 4.0 mg/ml, 2.4 mg/ml, 0.27 mg/ml, and 0.44 mg/ml, respectively determined as described [46]. Affinity purified IgG against GLURP.R0 were obtained as previously described [9]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Functional in vitro assays could provide insights into the efficacy of malaria vaccine candidates. For estimating the anti-parasite effect induced by a vaccine candidate, an accurate determination of live parasite count is an essential component of most in vitro bioassays. Although traditionally parasites are counted microscopically, a faster, more accurate and less subjective method for counting parasites is desirable. In this study mitochondrial dye (Mitotracker Red CMXRos) was used for obtaining reliable live parasite counts through flow cytometry. Both asynchronous and tightly synchronized asexual blood stage cultures of Plasmodium falciparum were stained with CMXRos and subjected to detection by flow cytometry and fluorescence microscopy. The parasite counts obtained by flow cytometry were compared to standard microscopic counts obtained through examination of Giemsa-stained thin smears. A comparison of the ability of CMXRos to stain live and compromised parasites (induced by either medium starvation or by anti-malarial drug treatment) was carried out. Finally, parasite counts obtained by CMXRos staining through flow cytometry were used to determine specific growth inhibition index (SGI) in an antibody-dependent cellular inhibition (ADCI) assay. Mitotracker Red CMXRos can reliably detect live intra-erythrocytic stages of P. falciparum. Comparison between staining of live with compromised parasites shows that CMXRos predominantly stains live parasites with functional mitochondria. Parasite counts obtained by CMXRos staining and flow cytometry were highly reproducible and can reliably determine the ability of IgG from hyper-immune individuals to inhibit parasite growth in presence of monocytes in ADCI assay. Further, a dose-dependent parasite growth inhibitory effect could be detected for both total IgG purified from hyper-immune sera and affinity purified IgGs against the N-terminal non-repeat region of GLURP in ADCI assays coupled with determination of parasite counts through CMXRos staining and flow cytometry. A flow cytometry method based on CMXRos staining for detection of live parasite populations has been optimized. This is a rapid and sensitive method with high inter-assay reproducibility which can reliably determine the anti-parasite effect mediated by antibodies in functional in vitro assays such as ADCI assay.
    Malaria Journal 07/2012; 11(1):235. DOI:10.1186/1475-2875-11-235 · 3.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hypogammaglobulinemia is common in Waldenström's macroglobulinemia. The etiology of this finding remains unclear, but it has been speculated to be based on tumor-induced suppression of the 'uninvolved' immunoglobulin production We evaluated the incidence of IgA and IgG hypogammaglobulinemia in 207 untreated patients with Waldenström's macroglobulinemia and investigated the associated clinicopathological findings and impact of therapy. We also sequenced eight genes (AICDA, BTK, CD40, CD154, NEMO, TACI, SH2D1A, UNG) implicated in immunoglobulin deficiency in 19 Waldenström's macroglobulinemia patients with IgA and/or IgG hypogammaglobulinemia. At baseline 63.3%, 58.0% and 49.3% of the 207 patients had abnormally low serum levels of IgA, IgG, or both. No association between IgA and IgG hypogammaglobulinemia and disease burden, serum IgM levels, beta(2)-microglobulin, International Prognostic Scoring System score, or incidence of recurrent infections was observed, although the presence of adenopathy and/or splenomegaly was associated with a lower incidence of hypogammaglobulinemia. Lower IgA and IgG levels were associated with disease progression in patients managed with a 'watch and wait' strategy. IgA and/or IgG levels remained abnormally low despite response to treatment, including complete remissions. A missense mutation in the highly conserved catalytic site of UNG was observed in a patient with hypogammaglobulinemia, warranting further study of this pathway in Waldenström's macroglobulinemia. IgA and IgG hypogammaglobulinemia is common in Waldenström's macroglobulinemia and persists despite therapeutic intervention and response. IgA and IgG hypogammaglobulinemia does not predict the risk of recurrent infections in patients with Waldenström's macroglobulinemia, although lower levels of serum IgA and IgG are associated with disease progression in Waldenström's macroglobulinemia patients being managed with a 'watch and wait' strategy.
    Haematologica 11/2009; 95(3):470-5. DOI:10.3324/haematol.2009.010348 · 5.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lymphoma, although rare, is the most common haematopoietic neoplasm encountered in horses and can occur at any age, with horses 4–10 years more commonly affected. Lymphoma can be classified into multicentric, alimentary, mediastinal, cutaneous and solitary. Clinical signs are typically nonspecific until the disease has progressed to end-stage at which time clinical signs reflect function of organ(s) involved. Horses with the cutaneous form of lymphoma typically present with multifocal skin lesions and no other clinical signs. Like the nonspecific clinical signs of lymphoma, results of complete blood count (CBC) and serum biochemistries are not often helpful with diagnosis, but lymphoma should be considered if anaemia, hyperfibrinogenaemia, hyperproteinaemia and hypoalbuminaemia are observed without a clear indication of infectious disease. Identification of neoplastic lymphocytes during cytological examination of a body cavity effusion can confirm the presence of lymphoma. Typically, ante mortem confirmation of lymphoma is made through histopathological examination of a biopsy or cytological examination of a fine needle aspirate of a suspected lesion. Observation of compression or destruction of normal tissue architecture by invading neoplastic cells during histological examination is indicative of lymphoma. Additional diagnostics that may improve our knowledge of equine lymphoma include detection of hormone receptors, immunophenotyping, and immunohistochemical analysis for tumour proliferation rates. Prognosis of horses with lymphoma depends on the form of lymphoma and stage at which the horse is presented but death is the common outcome of this disease. Current treatment options are surgical excision, radiation or administration of chemotherapeutic drugs. Treatment of horses with lymphoma can result in palliation and occasional resolution of this disease. Equine oncology is in its infancy, but through further documentation of horses with lymphoma and their response to therapy, a clearer understanding of the disease process and effective treatment of this neoplasm can be developed.
    03/2011; 23(4):205 - 213. DOI:10.1111/j.2042-3292.2010.00200.x
Show more